About
Eduardo Rene Salas has been a director of ADMA since December 2024 and serves on the Audit Committee. He has extensive experience as a financial executive serving both publicly traded and privately owned companies.
He has a B.A. in business administration from The University of Texas at San Antonio and completed Strategic Leadership programs at Harvard Business School and Northwestern University's Kellogg School of Management.
Roles
Adma Biologics, Inc.
Director · Current role
2024–present
Ernst & Young LLP
Senior client-serving audit partner · Retired in 2019.
2002-2019
Wellstat Therapeutics, LLC
Chief Financial Officer
2020-2022
Embody, Inc.
Lead independent director and audit committee chair · Private company acquired by Zimmer Biomet Holdings, Inc.
2021-2023
External Roles
Intra-Cellular Therapies, Inc.
Audit committee member
2022-2025
Director Compensation
FY 2025
Fees earned or paid in cash
$62,500
Stock awards (RSUs)
$174,986
Also at Adma Biologics, Inc.